Dermiselagon Development for EPP and XLP @checkrare
Dermiselagon Development for EPP and XLP  @checkrare
Uploaded October 2026 | Updated November 2026, 10 hours ago
Lukasz Jarzyna, Vice President of Rare Disease at LEO Pharma, discusses the Priority Review for dersimelagon in the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).

For the full interview, visit checkrare.com/priority-review-for-dersimelagon-in-the-treatment-of-erythropoietic-protoporphyria-and-x-linked-protoporphyria
Dermiselagon Development for EPP and XLPFDA Approves New Therapies for MPS IIIA and SMABreakthrough Therapy Designation to Cimzia for Pregnancy Complications in Antiphospholipid SyndromeEfficacy of Vosoritide to Treat HypochondroplasiaCh 5: Urgency of Diagnosis and Treatment in C3GAddressing Patient Experiences With IgA NephropathyCommon Concerns in Patients With Fabry DiseasePrader-Willi Syndrome: Diazoxide Choline Extended Release Improves HyperphagiaTherapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA ApprovalImpact of Gazyva Approval on Patients With Idiopathic Nephrotic SyndromeOvercoming Diagnostic Odysseys With Rare Hematologic ConditionsMyasthenia Gravis Clinical Research Highlights
CheckRare |

Dermiselagon Development for EPP and XLP

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER